Hepatitis D Virus (HDV) hitchhikes on Hepatitis B Virus (HBV), impacting 12 to 72 million globally with accelerated liver disease progression. Chronic HDV-HBV infection, deadlier than HBV alone, leads to cirrhosis and hepatocellular carcinoma. Limited awareness hampers diagnosis, but the HBV vaccine offers prevention. Interferon alfa shows efficacy, while bulevirtide and lonafarnib present promising therapies. With bulevirtide’s recent European approval, this review highlights HDV’s severe toll and evolving treatment landscape.
Journal Article by Negro F and Lok AS in JAMA